SLICC SLE Criteria

The SLICC criteria are validated criteria for making the diagnosis of lupus.

The global unit selector only affects unanswered questions
1.Acute or Subacute Cutaneous Lupus?
2.Chronic Cutaneous Lupus?
3.Nonscarring Alopecia?
4.Oral or Nasal Ulcers?
5.Joint Disease?
7.Abnormal urine findings (proteinuria or RBC casts)?
8.Biopsy-proven Lupus Nephritis?
9.Neurologic Involvement?
10.Hemolytic anemia?
11.Leukopenia or Lymphopenia?
16.Antiphospholipid Ab?
17.Low complement?
18.Direct Coombs' test?
Created by

1. Acute or Subacute Cutaneous Lupus?

More Information

Lupus malar rash (do not count if malar discoid)
Bullous lupus
Toxic epidermal necrolysis variant of SLE
Maculopapular lupus rash
Photosensitive lupus rash (in the absence of dermatomyositis)
or Subacute cutaneous lupus (nonindurated psoriaform and/or annular polycyclic lesions that resolve without scarring, although occasionally with postinflammatory dyspigmentation or telangiectasias)

Created by
0/18 completed

About this Calculator

In 2012, the Systemic Lupus International Collaborating Clinics (SLICC) proposed revised classification criteria were released in an effort to improve upon the 1997 American College of Rheumatology (ACR) classification criteria.

Some advantges of SLICC over ACR criteria include:

  • Patients with biopsy-confirmed lupus nephritis could still fail to fulfill ACR criteria.
  • ACR criteria included the possible duplication of highly correlated cutaneous features (such as malar rash and photosensitivity)
  • ACR criteria did not include other cutaneous manifestations (such as maculopapular or polycyclic rash)
  • ACR criteria did not include many neurologic manifestations of SLE
  • ACR criteria did not include relevant immunologic information such as low complement

SLICC criteria requires either that a patient satisfy at least 4 of 17 criteria, including at least 1 of the 11 clinical criteria and one of the six immunologic criteria, or that the patient has biopsy-proven nephritis compatible with SLE in the presence of antinuclear antibodies (ANA) or anti-double-stranded DNA (dsDNA) antibodies.

The SLICC criteria have been validated, and found to have greater sensitivity but lower specificity than the 1997 ACR classification criteria (sensitivity of 97 versus 83 percent and specificity of 84 versus 96 percent, respectively).

Despite the increased sensitivity compared with the ACR criteria, it should be noted that the SLICC criteria might delay the diagnosis of SLE in some patients, and some patients might not be classified at all.

Legal Notices and Disclaimer

© 2020 QxMD Software Inc., all rights reserved. No part of this service may be reproduced in any way without express written consent of QxMD. This information should not be used for the diagnosis or treatment of any health problem or disease. This information is not intended to replace clinical judgment or guide individual patient care in any manner. Click here for full notice and disclaimer.